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Objectives: To analyze predictors and long-term
consequence of type II endoleak in a large series of elective
EVAR.
Methods: Baseline characteristics, operative and
follow-up data of consecutive patients undergoing
EVAR were prospectively collected. Patients who devel-
oped type II endoleak according to CT scan and those
without were compared for baseline characteristic, mor-
tality, reintervention, conversion and aneurysm growth
after repair.
Results: 1412 consecutive patients (91.4% males;
mean age, 72.9) underwent elective EVAR in 1997-2012
and were subsequently followed for a mean of 54 6 42
months. 218 developed type II endoleak. Multivariate
analysis failed to identify type II endoleak signiﬁcant inde-
pendent predictors with the exception of age (P ¼ .026;
OR, 1.023) and neck thrombus (P ¼ .011; OR, .303).
Rates of type II endoleak were comparable regardless the
type of device but there was a tendency for lower rate
with most recent generation devices. Freedom from aneu-
rysm sac growth >5 mm (95.2% vs 42.4%; P < .001) rein-
tervention (92.3% vs 49.6%; P < .001) or conversion
(98.5% vs 80%; P < .001) at 120 months was higher in
patients without type II endoleak.
Fifty-two patients with type II endoleak underwent
reintervention. At 60 months, rates of persisting type II
endoleak were similar among patients with and without
reinterventions (49.8% vs 45.6%). There were no signiﬁ-
cant difference in persisting aneurysm growth >5 mm in
type II endoleak patients after reintervention and those
who remained untreated (57.1% vs 42.6%).
Cox regression identiﬁed type II endoleak as indepen-
dent predictor of aneurysm growth along with age and
cardiac disease.
There were four aneurysm ruptures during follow-up
in patients with type II endoleak. Late aneurysm related
mortality at 120 months was 3.8% vs 2.1% for patients
with and without type II endoleak.
Conclusions: Type II endoleak is a common marker
of EVAR failure reﬂecting multiple meanings. Occurrence
and consequences are challenging to be predicted and
treatment with reinterventions often results in failure.
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Objectives: Aortic infections, even with treatment,
have a high mortality and risk of recurrent infection and
limb loss. CAA has been proposed for in-line reconstruc-
tion to improve outcomes in this high-risk population.
Methods: A multi-center study using a standardized
database was performed at 14 of the highest volume insti-
tutions who used CAA for aortic infection.
Results: Two hundred and twenty patients (mean age
¼ 65; M:F ¼ 1.6/1) were treated since 2000 with 283
CAAs for prosthetic graft infection (59%), primary aortic
infection (17%), enteric ﬁstula/erosion (16%), mycotic
aneurysm (4%), and other (4%). Intra-op cultures indicated
infection in 66%, most frequently polymicrobial. Distal
anastomosis was to the femoral artery, iliac, then distal
aorta. 30-day mortality was 9% and procedure related
major complications occurred in 24%, including persistent
sepsis (n ¼ 17), graft thrombosis (n ¼ 9), graft/stump
rupture (n ¼ 8), recurrent CAA/aortic infection (n ¼ 8),
pseudoaneurysm (n ¼ 6), recurrence of AE ﬁstula (n ¼
4), and compartment syndrome (n ¼ 1). Hospital LOS
was 24 days. Ten (5%) required allograft explant; 2 devel-
oped CAA aneurysm requiring resection at 23 and 40 mo.
Primary graft patency and freedom from limb loss were
93% and 97%, respectively, at 5 yr. Patient survival was
75% at 1 yr and 51% at 5 yr.
Conclusions: This largest study indicates that CAA
allows in-line reconstruction of aortic infection with lower
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previously reported treatment options. Repair with CAA
is associated with low rates of aneurysm formation, recur-
rent infection, and limb loss.
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Genetics, Rotterdam, The NetherlandsFig.Objectives: To investigate the risk of postoperative
adverse events (PAE) in patients with familial AAA
(fAAA) vs sporadic AAA (spAAA).
Methods: Patients were derived from a prospective
database for EVAR. Family history was obtained by written
questionnaire (93% response rate). fAAA patients were
deﬁned as having $1 affected 1st-degree relative, and
excluding connective tissue disorders. Cardiovascular risk
factors, AAA morphology (neck, sac and iliac), and
follow-up (FU) information were scored. PAE was deﬁned
as a composite of secondary intervention, sac growth (>5
mm), and type I/III endoleak. PAE estimates were ob-
tained from Kaplan-Meier plots and multivariable Cox-
regression was used to explore the risk associated with
fAAA.
Results: 207 patients were included (90% men; age 71
6 8; FU 4.5 6 3 yrs), with 46 (22%) classiﬁed as fAAA.
Patients with fAAA were younger (68 vs 72 yrs; P ¼
.003) and less likely smokers (P ¼ .056). No difference
was observed in AAA morphology. After EVAR, fAAA
patients had signiﬁcantly more PAE (Fig), with a 2-fold
increase in risk (adjusted HR, 2.0; 95% CI, 1.1-3.8). Sac
growth was observed in 20% of fAAA vs 9% of spAAA (P ¼
.005), unrelated to presence of endoleak. There were no
further differences in individual components of PAE, nor in
overall survival.
Conclusions: Despite similar morphology, patients
with fAAA had more PAE, mainly due to sac growth. Until
the underlying cause is identiﬁed, patients with fAAA may
need closer surveillance.
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Objectives: This study aims to examine the shifting
trend in the management of true splenic artery aneurysms
(SAA) in an endovascular (EV) era.
Methods: A retrospective review of a single institution
experience with SAA was performed. Medical records and
imaging of 74 patients diagnosed with SAA between
1997 and 2012 were reviewed. This data was compared
to a historical cohort of 60 patients managed before 1974.
Results: A female predominance of 80% was noted, of
which 65% of women were multiparous and 13% reported
grand-multiparity ($6 pregnancies). Mean age at diagnosis
was 56 years (range, 32-80). Mean aneurysm size at diag-
nosis was 2.0 cm (range, 0.8-3.5). 31 patients (41%) were
followed conservatively and demonstrated no growth by
surveillance imaging. 43 patients underwent surgical
